{"id":95074,"date":"2026-07-01T05:55:03","date_gmt":"2026-07-01T05:55:03","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/95074\/"},"modified":"2026-07-01T05:55:03","modified_gmt":"2026-07-01T05:55:03","slug":"nurix-therapeutics-inc-nrix-price-target-raised-to-33-on-roche-partnership-value-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/95074\/","title":{"rendered":"Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value"},"content":{"rendered":"\n

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts<\/a>. Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the\u00a0best biotech stocks\u00a0on this list. <\/p>\n

TheFly reported on June 18 that Baird increased its price target on NRIX to $33 from $26 while maintaining an Outperform rating on the shares. The firm adjusted its valuation to account for the company’s partnership with Roche and continued progress across its clinical programs. <\/p>\n

\"Nurix<\/a> Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value <\/p>\n

Separately, earlier on June 11, Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported updated clinical findings from its ongoing NX-5948-301 Phase 1a\/b trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The data showed continued durable responses in heavily pretreated patients along with encouraging activity in earlier treatment settings. Across 142 Phase 1a\/b CLL patients, bexobrutideg demonstrated a favorable safety profile, with no dose-limiting toxicities or treatment-related Grade 5 adverse events. In relapsed\/refractory CLL patients, the therapy achieved an objective response rate of 83% with a median progression-free survival of 22.1 months. Earlier-line cohorts also showed strong activity, including ORRs of 92.9% and 84.2% in evaluated groups. The results support further development of bexobrutideg, including a planned Phase 3 monotherapy program. <\/p>\n

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies and other treatments for cancer and autoimmune diseases. <\/p>\n

While we acknowledge the potential of NRIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the <\/a>best short-term AI stock<\/a>. <\/p>\n

READ NEXT: 33 Stocks That Should Double in 3 Years<\/a> and 15 Stocks That Will Make You Rich in 10 Years<\/a>\u00a0 <\/p>\n

Disclosure: None. Follow Insider Monkey on Google News<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Nurix Therapeutics,…\n","protected":false},"author":2,"featured_media":95075,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[41362,2039,41250,41221,134],"class_list":["post-95074","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-chronic-lymphocytic-leukemia","tag-inc","tag-nrix","tag-nurix-therapeutics","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116843179141514174","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/95074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=95074"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/95074\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/95075"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=95074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=95074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=95074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}